Following the European Society for Medical Oncology (ESMO) Congress 2024, Samantha Armstrong, MD, Indiana University, and co-host of the podcast “Two Onc Docs,” offers a review of two genitourinary (GU) oncology abstracts that were presented. A notable, practice-changing abstract was the NIAGARA trial presented by Dr. Thomas Powles at the Presidential Symposium on Sunday, September 15. This study involved 1,063 patients with muscle-invasive bladder cancer eligible for platinum-based chemotherapy followed by radical cystectomy. Patients were randomized 1:1 to receive either standard ...
mCSPC
Advertisement
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Future Directions in Metastatic PC: Exploring Monotherapy, Novel Therapies, and Strategic Sequencing
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen.
The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies.
The panel explores the challenges involved in managing mHSPC, focusing on difficulties with obtaining PSMA scans.
Dr. Pobel offers an overview of the ancillary study of the PEACE-1 trial, including how immunohistochemistry was used.
Advertisement
Prostate Cancer Knowledge Hubs
Conference Coverage
The first part of five segments from the live podcast, roundtable session on radioligands.
During the final part of this panel, novel ADCs are explored and analyzed for use in different settings.
During the fourth segment of this panel, novel ADCs including HER3, Nectin-4, and BT8009 are analyzed.
In the third part of this panel, the use of HER2 ADCs in bladder cancer is explored.
In the second segment of this panel, the use of sacituzumab govitecan monotherapy and combinations is discussed.
In the first part of this panel, the use and impact of enfortumab vedotin in the bladder cancer landscape is considered.
Advertisement
Advertisement
Latest News
The first part of five segments from the live podcast, roundtable session on radioligands.
Part three of this prostate cancer roundtable covers prognostic factors such as Gleason scores and genomic assays.
Part two of this roundtable features a discussion on the role of bone scans compared to the newer PSMA PET scans.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.